Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
复制标题
DOI：
10.1046/j.1463-1326.2001.00160.x
复制
发表时间：
2001-12-01
影响因子：
5.8
通讯作者：
Ugander, L
中科院分区：
文献类型：
--
作者：
Hermann, LS;Kalén, J;Ugander, L
目的：目的：评价二甲双胍对胰岛素治疗2型糖尿病的辅助作用。方法：肥胖和超重的2型糖尿病患者接受胰岛素治疗至少1年。和血糖控制不佳（HbA（1c）>参考上限+2%）的患者纳入一项随机、双盲、安慰剂对照研究。患者接受二甲双胍（850 mg b.i.d.）或安慰剂添加到他们通常的胰岛素，这是稳定在3个月的安慰剂导入期，但此后试图保持不变。两名患者在ron-in期间退出。基线时二甲双胍组（n=16）和安慰剂组（n=19）之间无差异。大多数患者接受多次胰岛素注射。通过添加二甲双胍改善代谢控制。在3、6、9和12个月时，HbA（1c）相对于基线的平均变化显示组间存在高度显著性差异。平均变化（单位百分比+/- s.d.）12个月时为-1.1 +/-0.7% vs. + 0.3 +/-0.8%（p
Aim: To assess the adjunct effect of metformin to insulin in type 2 diabetes.Methods: Obese and overweight type 2 diabetes patients treated with insulin for at least 1 year. and with poor glycaemic control (HbA(1c) > upper reference level + 2%), were included in a randomised, double-blind, placebo-controlled study. Patients were treated for 12 months with either metformin (850 mg b.i.d.) or placebo added to their usual insulin, which was stabilized during a 3-month placebo run-in period, but thereafter attempted to be unchanged.Results: Thirty-seven patients were included. Two patients dropped out during ron-in. There were no differences between the metformin (n=16) and placebo (n=19) group at baseline. Most patients received multiple insulin injections. Metabolic control was improved by addition or metformin. Mean change in HbA(1c) from baseline showed highly significant difference between groups at 3, 6, 9 and 12 months. Mean change (percentage units +/- s.d.) at 12 months was -1.1 +/-0.7% vs. + 0.3 +/-0.8% (p